Carole Guillonneau
  • E-mail :[email]
  • Phone : +33 2 40 08 75 96
  • Location : Nantes, France
Last update 2016-08-02 15:10:58.864

Carole Guillonneau Biology of CD8+CD45RClow Tregs and clinical development

Course and current status

1st class research Scientist - CNRS

Inserm UMR 1064 – ITUN – Center for Research in Transplantation and Immunology

Tel 1 : +33 (0)2 40 08 75 96

Fax : +33 (0)2 40 08 74 11

Email :

Adresse postale : CHU Hotel Dieu 30 Bd Jean Monnet 44093 Nantes France


2015: Habilitation à Diriger des Recherches, University of Nantes

2005: Ph.D., Red Blood Cell Biology, University of Paris 7

Research Experience:

2010-present: Group Leader of Biology of CD8+CD45RClow Tregs and clinical development in the Gene and cell engineering in immunology and regenerative medicine team
Inserm UMR 1064 – ITUN – Center for Research in Transplantation and Immunology

2006-2009: Post-doctorate – Marie Curie Fellow in the lab of Nobel Laureate Pr. Peter Doherty, Department of Microbiology and Immunology, University of Melbourne, Australia

Understanding and manipulating TCR/MHCpeptide interaction in CD8+ T cell response to influenza.

2002-2005: Ph.D. student in the lab of Dr. Ignacio Anegon, Inserm U437, Nantes, France.
Induction of tolerance in transplantation using costimulation blockade.

Scientific summary

Scientific interests:

Regulatory T cells have been described as being capable of inducing tolerance to allogeneic organs, however, CD8+ Treg, while demonstrated as crucial in some diseases, have been put aside and their role and potential in tolerance remain unclear. My projects investigate both in rodent and human antigen-specific regulatory CD8+ T lymphocytes, their biology at a cellular and molecular level, their generation upon encounter with an antigen and their role in transplantation tolerance and autoimmunity. These aspects are particularly important in current transplantation since new immunosuppressive strategies are based on the generation of a donor-specific tolerance. Our long term goals are to allow the establishment of new strategies of tolerance induction and better prognosis/diagnosis of patients before and after transplantation.


On-going projects:

1. Molecular characterization of CD8+ Tregs identity using mRNA sequencing

2. Determination of CD8+ Tregs differentiation, stability and distribution: role of Aire in the generation of antigen-specific CD8+ Tregs

3. Characterization of CD8+ Tregs specificity: Characteristics and roles of the TCR/MHC/peptide interaction in rat and human

4. In vivo evaluation of CD8+ Tregs contribution in experimental and human transplantation: CD8+CD45RClow Tregs as a cellular therapy

5. Development of novel therapeutic strategies to induce immune-suppression to favor allograft tolerance using CD8+ Tregs characteristics

6. Generation of CD8+ Tregs from pluripotent stem cells

7. Role of human CD8+ Tregs in autoimmune diseases: the case of multiple sclerosis

Recent publications from the group

Bézie S. and Guillonneau C. “In vitro and in vivo assessment of T, B and myeloid cells suppressive activity and determination of humoral responses from transplant recipients”. Journal of Visualized Experiments. In press.

Boucault L., Bézie S., Ossart J. and Guillonneau C., Immune tolerance in transplantation. 2016, Book Chapter “Organ Transplantation”. Series InTech - open science, open minds. In press.

Bézie S., Picarda E., Ossart J., Martinet B., Anegon I. and Guillonneau C. Compensatory regulatory networks between CD8 T, B and myeloid cells in organ transplantation tolerance. J. Immunol. 2015 Nov 9. pii: 1500473.

Bézie S., Picarda E., Ossart J., Tesson L., Usal C., Renaudin K., Anegon I. and Guillonneau C. Interleukin-34, a new Treg-specific cytokine mediator of transplant tolerance. J. Clin Invest. 2015, Oct 1;125(10):3952-64.

Guillonneau C. Efficacy of Myeloid Derived Suppressor Cells on Transplant Survival. Transplantation. 2015 Oct;99(10):2017-9.

Picarda E., Ossart J., Bézie S. and Guillonneau C. Key role of allopeptide-specific CD8+ Tregs in transplantation. Med Sci (Paris). Med Sci (Paris). 2015 Jan;31(1):22-24.

Picarda E., Bézie S., Venturi V., Echasserieau K., Meriau E., Renaudin K., Delhumeau A., Brouard S., Bernardeau K., Anegon I. and Guillonneau C.. MHC class II allo-peptide activates TCR-biased-CD8+ Tregs and suppresses organ rejection. J. Clin Invest., 2014. Jun 2;124(6):2497-512.


Funding Support

Our research is partially funded by the following grants:

2016 : Paris Scientifique Région Pays de la Loire

2016-2018:     Agence de la Biomedecine “Recherche et Greffe”

2016 :  French Ministry of Education and Research Labex IGO program grant

2015 :  DHU oncogreffe

2015:   Fond de Maturation Ouest Valorisation

2015:   Fondation ARSEP annual grant

2015-2018:     INSERM-Region Pays de la Loire Fellowship for a PhD student

2015:   Agence de la Biomedecine “Recherche et Greffe”

2015:   Proof of Concept funding from Inserm-Transfert

2014 : BD Biosciences Europe Research grant

2014:   DHU oncogreffe

2014 : Subvention « Maladies Rares » from Fondation pour la Recherche Médicale for a PhD thesis

2014:   Funding « Transplantation and Cellular Therapy 2014 » to the Victor et Erminia Mescle prize from Fondation pour la Recherche Médicale (FRM)

2014:   Junior Clinical Science Grant from ESOT

2014-2015      Agence de la Biomedecine “Recherche et Greffe”



13-06-16 // Carole Guillonneau laureate Prix France Transplant 2016

27-05-16 // Séverine Bezie ARSEP foundation award for best poster presentation

02-04-16 // Carole Guillonneau (Mentor) and Séverine Bézie (Mentee) receive the 2016 TTS-SFT International Transplantation Science Mentee-Mentor Award

07-09-2015 // Young Investigator Award to Carole Guillonneau, 17th Congress of the European Society for Organ Transplantation (ESOT), Brussels, Belgium

Image d’exemple